Download PDF
Hamostaseologie 2023; 43(01): 022-027
DOI: 10.1055/a-1986-1556
Original Article

Diagnostic Performance of a Particle Gel Immunoassay in Vaccine-Induced Immune Thrombotic Thrombocytopenia

Günalp Uzun
1   Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany
,
Karina Althaus
1   Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany
2   Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, Tuebingen, Germany
,
Stefanie Hammer
1   Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany
,
Yvonne Wanner
1   Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany
,
Stefanie Nowak-Harnau
1   Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany
,
Sigrid Enkel
1   Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany
,
Tamam Bakchoul
1   Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany
2   Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, Tuebingen, Germany
› Author Affiliations Funding/Acknowledgments This work was supported by grants from the German Research Foundation and from the Herzstiftung to T.B. (BA5158/4 and TSG-Study), by special funds from the state of Baden-Württemberg for coagulation research and blood donation service of German Red Cross to T.B. This study was partially presented as a poster contribution at the 17th Annual Meeting of the German Society for Clinical Chemistry and Laboratory [17. Jahrestagung der Deutschen Gesellschaft für Klinische Chemie und Laboratoriumsmedizin], October 13–14, 2022, in Mannheim, Germany. We thank Barbara Gubitz for her help during patient chart review.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but serious complication of adenoviral vector-based COVID-19 vaccines. Similar to heparin-induced thrombocytopenia (HIT), antibodies reacting to platelet factor 4 (PF4) are responsible for platelet activation in VITT. The diagnosis of VITT includes the detection of anti-PF4 antibodies. Particle gel immunoassay (PaGIA) is one of the rapid immunoassays that is commonly used in the diagnosis of HIT to detect anti-PF4 antibodies. The aim of this study was to investigate the diagnostic performance of PaGIA in patients suspected of VITT. In this retrospective, single-center study, the correlation between PaGIA, enzyme immunoassay (EIA), and modified heparin-induced platelet aggregation assay (HIPA) in patients with findings suggestive of VITT was investigated. A commercially available PF4 rapid immunoassay (ID PaGIA H/PF4, Bio-Rad-DiaMed GmbH, Switzerland) and an anti-PF4/heparin EIA (ZYMUTEST HIA IgG, Hyphen Biomed) were used according to manufacturer's instructions. Modified HIPA was accepted as the gold standard test. Between March 8 and November 19, 2021, a total of 34 samples from clinically well-characterized patients (14 males, 20 females, mean age: 48.2 ± 18.2 years) were analyzed with PaGIA, EIA, and modified HIPA. VITT was diagnosed in 15 patients. Sensitivity and specificity of PaGIA were 54 and 67%, respectively. Anti-PF4/heparin optical density values were not significantly different between PaGIA positive and negative samples (p = 0.586). The sensitivity and specificity of EIA, on the other hand, were 87 and 100%, respectively. In conclusion, PaGIA is not reliable in the diagnosis of VITT because of its low sensitivity and specificity.

Keywords

diagnostic test - platelet factor 4 - rapid immunoassay - platelet immunology

Authors' Contributions

G.U., K.A., and T.B. designed the study. G.U., K.A., S.H., Y.W., S.N-H., and S.E. collected the clinical data and analyzed the test results. G.U., K.A., and T.B. performed the statistical analyses, interpreted the results, and wrote the manuscript. All authors read and approved the manuscript.




Publication History

Received: 14 October 2022

Accepted: 22 November 2022

Article published online:
20 February 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Feikin DR, Higdon MM, Abu-Raddad LJ. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 2022; 399 (10328): 924-944
    CrossrefPubMedGoogle Scholar
  • 2 World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Published December 15, 2021. Accessed December 15, 2021 at: https://covid19.who.int/
    PubMedGoogle Scholar
  • 3 Althaus K, Möller P, Uzun G. et al. Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. Haematologica 2021; 106 (08) 2170-2179
    CrossrefPubMedGoogle Scholar
  • 4 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101
    CrossrefPubMedGoogle Scholar
  • 5 Scully M, Singh D, Lown R. et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 (23) 2202-2211
    CrossrefPubMedGoogle Scholar
  • 6 Schultz NH, Sørvoll IH, Michelsen AE. et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 (22) 2124-2130
    CrossrefPubMedGoogle Scholar
  • 7 van de Munckhof A, Krzywicka K, Aguiar de Sousa D. et al. Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination. Eur J Neurol 2022; 29 (01) 339-344
    CrossrefPubMedGoogle Scholar
  • 8 Pavord S, Scully M, Hunt BJ. et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med 2021; 385 (18) 1680-1689
    CrossrefPubMedGoogle Scholar
  • 9 Bourguignon A, Arnold DM, Warkentin TE. et al. Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med 2021; 385 (08) 720-728
    CrossrefPubMedGoogle Scholar
  • 10 Lentz SR. Cooling down VITT with IVIG. Blood 2021; 138 (11) 921-922
    CrossrefPubMedGoogle Scholar
  • 11 Uzun G, Althaus K, Singh A. et al. The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia. Blood 2021; 138 (11) 992-996
    CrossrefPubMedGoogle Scholar
  • 12 Marini I, Uzun G, Jamal K, Bakchoul T. Treatment of drug-induced immune thrombocytopenias. Haematologica 2022; 107 (06) 1264-1277
    CrossrefPubMedGoogle Scholar
  • 13 Nazy I, Sachs UJ, Arnold DM. et al. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost 2021; 19 (06) 1585-1588
    CrossrefPubMedGoogle Scholar
  • 14 Oldenburg J, Klamroth R, Langer F. et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie 2021; 41 (03) 184-189
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Warkentin TE, Greinacher A. Laboratory testing for VITT antibodies. Semin Hematol 2022; 59 (02) 80-88
    CrossrefPubMedGoogle Scholar
  • 16 Favaloro EJ. Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. Int J Lab Hematol 2021; 43 (04) 559-570
    CrossrefPubMedGoogle Scholar
  • 17 Meyer O, Salama A, Pittet N, Schwind P. Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4). Lancet 1999; 354 (9189): 1525-1526
    CrossrefPubMedGoogle Scholar
  • 18 Pouplard C, Gueret P, Fouassier M. et al. Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2007; 5 (07) 1373-1379
    CrossrefPubMedGoogle Scholar
  • 19 Schallmoser K, Drexler C, Rohde E. et al. The particle gel immunoassay as a rapid test to rule out heparin-induced thrombocytopenia?. J Thorac Cardiovasc Surg 2009; 137 (03) 781-783
    CrossrefPubMedGoogle Scholar
  • 20 Sachs UJ, Cooper N, Czwalinna A. et al. PF4-dependent immunoassays in patients with vaccine-induced immune thrombotic thrombocytopenia: results of an interlaboratory comparison. Thromb Haemost 2021; 121 (12) 1622-1627
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Tiede A, Sachs UJ, Czwalinna A. et al. Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood 2021; 138 (04) 350-353
    CrossrefPubMedGoogle Scholar
  • 22 Hörber S, Lehmann R, Fritsche L. et al. Lifestyle intervention improves prothrombotic coagulation profile in individuals at high risk for type 2 diabetes. J Clin Endocrinol Metab 2021; 106 (08) e3198-e3207
    CrossrefPubMedGoogle Scholar
  • 23 Greinacher A, Langer F, Makris M. et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT): update on diagnosis and management considering different resources. J Thromb Haemost 2022; 20 (01) 149-156
    CrossrefPubMedGoogle Scholar
  • 24 Platton S, Bartlett A, MacCallum P. et al. Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination. J Thromb Haemost 2021; 19 (08) 2007-2013
    CrossrefPubMedGoogle Scholar
  • 25 Reilly-Stitt C, Jennings I, Kitchen S. et al. Anti-PF4 testing for vaccine-induced immune thrombocytopenia and thrombosis (VITT): results from a NEQAS, ECAT and SSC collaborative exercise in 385 centers worldwide. J Thromb Haemost 2022; 20 (08) 1875-1879
    CrossrefPubMedGoogle Scholar
  • 26 Huynh A, Kelton JG, Arnold DM, Daka M, Nazy I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature 2021; 596 (7873): 565-569
    CrossrefPubMedGoogle Scholar
  • 27 Singh A, Toma F, Uzun G. et al. The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia. Blood 2022; 139 (23) 3430-3438
    CrossrefPubMedGoogle Scholar
  • 28 Fortner R. AstraZeneca's COVID-19 (mis)adventure and the future of vaccine equity. BMJ 2022; 379: o2592
    CrossrefPubMedGoogle Scholar
  • 29 Factbox: Vaccines delivered under COVAX sharing scheme for poorer countries. Accessed November 19, 2022 at: https://www.reuters.com/business/healthcare-pharmaceuticals/vaccines-delivered-under-covax-sharing-scheme-poorer-countries-2022-01-03/
    PubMedGoogle Scholar